NRIX
HealthcareNurix Therapeutics, Inc. · Biotechnology · $2B
What is Nurix Therapeutics, Inc.?
Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies targeting cancer and immune disorders. Headquartered in San Francisco, the company has built a pipeline around targeted protein degradation and immune pathway modulation.
Nurix generates revenue primarily through strategic collaboration agreements rather than product sales, as its therapies remain in clinical development. The company applies its proprietary DEL-linker platform to design orally available small molecules that degrade or inhibit specific disease-driving proteins. Key partnerships with Gilead Sciences and Sanofi provide funding and validation for its pipeline programs targeting B-cell malignancies, autoimmune diseases, and solid tumors.
Nurix was incorporated in 2009 and is headquartered in San Francisco, California.
- NX-2127: oral BTK degrader for relapsed or refractory B-cell malignancies
- NX-5948: oral BTK degrader targeting B-cell cancers and autoimmune diseases
- NX-1607: oral CBL-B inhibitor for immuno-oncology indications
- DeTIL-0255: Phase 1 program for gynecologic cancers including ovarian and cervical
- Gilead and Sanofi collaborations funding cancer and immune disease research
Is NRIX a Good Stock to Buy?
UQS Score rates NRIX as Poor overall, reflecting the early-stage nature and financial profile typical of clinical-stage biotechs.
The Risk pillar stands out as the relative bright spot in NRIX's profile, suggesting the company carries a manageable near-term risk structure compared to some peers — likely supported by its collaboration-backed cash runway.
Both the Quality and Moat pillars register as Weak, consistent with a pre-revenue biotech that has yet to establish durable competitive advantages or consistent financial performance. The Valuation pillar reads as Elevated, meaning the market is pricing in considerable future success.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does NRIX pay dividends?
No — Nurix Therapeutics, Inc. does not currently pay a dividend.
Nurix Therapeutics does not pay a dividend, which is standard for clinical-stage biopharmaceutical companies. Available capital is directed toward funding clinical trials, research operations, and partnership obligations. Investors in NRIX are typically seeking potential long-term appreciation from pipeline success rather than income.
When does NRIX report earnings?
Nurix Therapeutics reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a clinical-stage company, Nurix's quarterly results center on collaboration revenue, operating expenses, and cash position rather than product sales. Pipeline milestones and partnership updates tend to drive more market attention than headline earnings figures.
For the most recent quarter's results and management commentary, visit Nurix Therapeutics' investor relations page directly.
NRIX Price History
-41.1% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Nurix Therapeutics, Inc.?
Based on Nurix Therapeutics, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
NRIX Long-term Outlook
The Growth pillar for NRIX sits at Neutral, reflecting the binary nature of clinical-stage biotech development — meaningful upside exists if pipeline candidates advance, but progress is inherently uncertain. The Elevated Valuation pillar suggests the current share price already embeds optimistic assumptions about future pipeline outcomes. The Good Risk rating provides some reassurance around near-term financial stability, but the Weak Quality and Moat pillars indicate the company has not yet translated its science into durable financial strength.
Growth drivers
- Advancement of BTK degrader programs into later-stage clinical trials
- Expansion or deepening of Gilead and Sanofi collaboration agreements
- Potential new data readouts from CBL-B inhibitor and adoptive T-cell programs
Key risks
- Clinical trial failure or delays across any pipeline program
- Elevated valuation leaves limited margin of safety if data disappoints
- Dependence on collaboration partners for a significant portion of funding
NRIX vs Peers
Nurix operates in a competitive clinical-stage biotech landscape alongside companies pursuing differentiated approaches to cancer and immune disease.
Amylyx focuses on neurodegenerative diseases rather than oncology, giving it a distinct therapeutic focus from Nurix's cancer and immune disorder pipeline.
Palvella targets rare skin diseases with its pipeline, representing a narrower and different patient population than Nurix's B-cell malignancy and autoimmune programs.
Immatics pursues T-cell-redirecting cancer therapies, overlapping with Nurix in immuno-oncology but using biologic rather than small molecule approaches.
Frequently Asked Questions
What does Nurix Therapeutics do?
Nurix Therapeutics discovers and develops orally available small molecule therapies for cancer and immune disorders. Its pipeline includes BTK degraders targeting B-cell malignancies and CBL-B inhibitors for immuno-oncology. The company funds much of its research through strategic collaborations with Gilead Sciences and Sanofi.
Does NRIX pay dividends?
No, Nurix Therapeutics does not pay a dividend. Clinical-stage biotechs typically reinvest all available capital into research and development. Investors in NRIX are generally seeking potential appreciation from pipeline progress rather than income distributions.
When does NRIX report earnings?
Nurix reports financial results quarterly, in line with standard US public company practice. Because it is pre-commercial, results focus on collaboration revenue, R&D spending, and cash runway. Check the company's investor relations page for the current reporting schedule.
Is NRIX a good stock to buy?
UQS Score rates NRIX as Poor overall, driven by Weak Quality and Moat pillars and an Elevated Valuation. The Risk pillar is the relative strength. Whether NRIX fits a portfolio depends on an investor's tolerance for clinical-stage biotech risk. The full pillar breakdown is available to UQS Pro members.
Is NRIX overvalued?
The UQS Valuation pillar for NRIX is rated Elevated, suggesting the market is pricing in considerable pipeline success. For a pre-revenue biotech, valuation is inherently forward-looking and tied to clinical outcomes. Investors should weigh this against the binary risk of drug development.
How does NRIX compare to its competitors?
Nurix differentiates itself through its small molecule protein degradation platform and oral drug candidates, contrasting with biologics-focused peers. Competitors like Immatics pursue T-cell therapies, while Amylyx and Palvella operate in entirely different disease areas. UQS Pro members can view side-by-side pillar comparisons.
What is NRIX's market cap bracket?
Nurix Therapeutics is classified as a small-cap company. This places it in a segment of the market where liquidity can be lower and share price volatility tends to be higher than large- or mega-cap peers, particularly given its clinical-stage status.
Who founded Nurix Therapeutics?
Nurix was originally incorporated in 2009 under the name Nurix Inc. before rebranding to Nurix Therapeutics, Inc. in October 2018. Founding details are widely available through the company's public filings and corporate history disclosures.
Is NRIX a long-term quality investment?
As a long-term quality indicator, UQS rates NRIX as Poor, reflecting weak fundamentals and an unproven competitive moat at this stage. Long-term outcomes depend heavily on clinical trial results and the ability to commercialize pipeline assets. Pro members can explore the full pillar profile to assess fit.
What is the main competitive advantage of Nurix Therapeutics?
Nurix's core differentiation lies in its targeted protein degradation platform, which enables the design of orally available small molecules that eliminate disease-driving proteins rather than simply inhibiting them. This approach has attracted partnerships with major pharmaceutical companies, lending external validation to the science.
What sector does NRIX belong to?
Nurix Therapeutics operates in the Healthcare sector, specifically within the biopharmaceutical and clinical-stage drug development segment. Investors can explore other [healthcare stocks scored by UQS](/sector/healthcare) for broader sector context.
Is NRIX a growth stock or value stock?
With a Neutral Growth pillar and an Elevated Valuation pillar, NRIX sits in an uncertain middle ground. The market assigns a growth-oriented premium, but the pipeline has not yet delivered the milestones needed to confirm that trajectory. It does not fit a traditional value profile.
Unlock Full NRIX Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View exact scores across all five UQS pillars
- ✓Access detailed financial metrics and trend data
- ✓Compare NRIX side-by-side with sector peers
- ✓See the complete Quality and Moat breakdown
- ✓Track Valuation changes over time with Pro tools
- ✓Get the full analyst-style view in one dashboard
Pro Analysis
NRIX — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 6, 2026 | 26.0 | 3.7 | 18.0 | 46.6 | 74.9 | 0.0 | -0.1 |
| Apr 18, 2026 | 26.1 | 3.7 | 18.0 | 47.0 | 74.9 | 0.0 | -0.1 |
| Apr 11, 2026 | 26.2 | 3.7 | 18.0 | 47.4 | 74.9 | 0.0 | +0.3 |
| Apr 9, 2026 | 25.9 | 3.7 | 18.0 | 46.2 | 74.9 | 0.0 | +1.0 |
| Apr 2, 2026 | 24.9 | 3.7 | 18.0 | 46.2 | 68.3 | 0.0 | — |
NRIX — Pillar Breakdown
Quality
— 3.7/100 (25%)Nurix Therapeutics, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 46.6/100 (20%)Nurix Therapeutics, Inc. shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 74.9/100 (15%)Nurix Therapeutics, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Nurix Therapeutics, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 18/100 (25%)Nurix Therapeutics, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for NRIX.
Score Composition
Financial Data
More Stock Analysis
How is the NRIX UQS Score Calculated?
The UQS (Unified Quality Score) for Nurix Therapeutics, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Nurix Therapeutics, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Nurix Therapeutics, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.